Constance Delaugerre

Summary

Country: France

Publications

  1. ncbi request reprint Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097)
    Constance Delaugerre
    Department of Virology, Pitié Salpetrière Hospital Paris, Paris, France
    J Med Virol 77:345-50. 2005
  2. ncbi request reprint Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF
    Constance Delaugerre
    Department of Virology, Necker Enfants Malades Hospital, 149 rue de Sevres, 75015 Paris, France
    J Clin Virol 32:241-4. 2005
  3. ncbi request reprint Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir
    Constance Delaugerre
    Service de Virologie EA 3620, Hopital Necker Enfants Malades, Paris, France
    J Acquir Immune Defic Syndr 37:1269-75. 2004
  4. ncbi request reprint Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey
    Constance Delaugerre
    Department of Virology EA3620, Necker Hospital, Paris, France
    AIDS 21:1365-7. 2007
  5. pmc Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy
    Marc Wirden
    Department of Virology, INSERM EMI 0214, Pitie Salpetriere Hospital, Paris, France
    Antimicrob Agents Chemother 48:644-7. 2004
  6. doi request reprint Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France
    Marie Laure Chaix
    Université Paris Descartes EA 3620, AP HP, Laboratoire de Virologie, CHU Necker Enfants Malades, Paris, France
    AIDS 23:717-24. 2009
  7. ncbi request reprint Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure
    Anne Genevieve Marcelin
    Department of Virology, Pitié Salpêtrière Hospital and University Paris VI Pierre et Marie Curie, Paris, France
    J Med Virol 72:162-5. 2004
  8. ncbi request reprint Change to a once-daily combination including boosted atazanavir in HIV-1-infected children
    Eugenia Macassa
    Unité d Immunologie Hématologie Pédiatrique, Paris, France
    Pediatr Infect Dis J 25:809-14. 2006
  9. doi request reprint Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen
    Constance Delaugerre
    Virology Department, Saint Louis Hospital APHP, Paris, France
    AIDS 22:1809-13. 2008
  10. pmc Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs
    Marc Wirden
    Department of Virology, Pitié Salpêtrière Hospital Department of Pharmacology, Bichat Hospital, Paris, France
    J Clin Microbiol 41:2713-5. 2003

Collaborators

Detail Information

Publications64

  1. ncbi request reprint Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097)
    Constance Delaugerre
    Department of Virology, Pitié Salpetrière Hospital Paris, Paris, France
    J Med Virol 77:345-50. 2005
    ..These results suggest that pharmacological enhancement might overcome viral resistance and that there is some benefit in adding the activity of several boosted-PIs to improve the response to a salvage regimen...
  2. ncbi request reprint Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF
    Constance Delaugerre
    Department of Virology, Necker Enfants Malades Hospital, 149 rue de Sevres, 75015 Paris, France
    J Clin Virol 32:241-4. 2005
    ..The high selective pressure on the same resistance pathway was probably associated with the loss of antiviral potency, even in well-controlled patient...
  3. ncbi request reprint Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir
    Constance Delaugerre
    Service de Virologie EA 3620, Hopital Necker Enfants Malades, Paris, France
    J Acquir Immune Defic Syndr 37:1269-75. 2004
    ..In pretreated children, LPV plasma levels should be optimized in an attempt to achieve sufficient drug concentrations to overcome the resistance level...
  4. ncbi request reprint Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey
    Constance Delaugerre
    Department of Virology EA3620, Necker Hospital, Paris, France
    AIDS 21:1365-7. 2007
    ..In both cases, infection was caused by CCR5 viruses and no rapid clinical progression to AIDS after primary infection was observed...
  5. pmc Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy
    Marc Wirden
    Department of Virology, INSERM EMI 0214, Pitie Salpetriere Hospital, Paris, France
    Antimicrob Agents Chemother 48:644-7. 2004
    ....
  6. doi request reprint Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France
    Marie Laure Chaix
    Université Paris Descartes EA 3620, AP HP, Laboratoire de Virologie, CHU Necker Enfants Malades, Paris, France
    AIDS 23:717-24. 2009
    ....
  7. ncbi request reprint Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure
    Anne Genevieve Marcelin
    Department of Virology, Pitié Salpêtrière Hospital and University Paris VI Pierre et Marie Curie, Paris, France
    J Med Virol 72:162-5. 2004
    ....
  8. ncbi request reprint Change to a once-daily combination including boosted atazanavir in HIV-1-infected children
    Eugenia Macassa
    Unité d Immunologie Hématologie Pédiatrique, Paris, France
    Pediatr Infect Dis J 25:809-14. 2006
    ..Pediatric experience with atazanavir combined with antiretroviral drugs administered once daily is very limited...
  9. doi request reprint Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen
    Constance Delaugerre
    Virology Department, Saint Louis Hospital APHP, Paris, France
    AIDS 22:1809-13. 2008
    ..Limited data are available on resistance pattern emerging in patients failing DRV/r and on subsequent remaining protease inhibitor options...
  10. pmc Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs
    Marc Wirden
    Department of Virology, Pitié Salpêtrière Hospital Department of Pharmacology, Bichat Hospital, Paris, France
    J Clin Microbiol 41:2713-5. 2003
    ..These data suggest that these compounds have lost all of their in vivo antiviral activity in such cases...
  11. ncbi request reprint Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    J Med Virol 74:16-20. 2004
    ..There was no relation between the resistance pathways selected with either APV or ritonavir plasma minimal concentration, but higher APV plasma minimal concentration were associated with a lower rate of resistance mutations selection...
  12. ncbi request reprint Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone
    Philippe Flandre
    INSERM U 943, Paris, France
    Antivir Ther 14:93-7. 2009
    ..The objective of this study was to determine prognostic factors of VR in patients receiving LPV/r monotherapy...
  13. ncbi request reprint Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children
    Constance Delaugerre
    Department of Virology, Necker Hospital, Paris, France
    J Med Virol 79:1261-9. 2007
    ..In conclusion, antiretroviral resistance is common among treated HIV-1-infected children and prevalence was similar with those observed in adult population in the same year period. However, adolescent boys seem to be at greater risk...
  14. doi request reprint Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study
    Lambert Assoumou
    INSERM, U 943, Paris, France
    J Antimicrob Chemother 68:1400-5. 2013
    ..Surveillance of HIV-1 drug resistance in treated patients with plasma viral load (VL) >50 copies/mL...
  15. doi request reprint Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen
    Anne Genevieve Marcelin
    AP HP, Pitie Salpetriere Hospital, Pierre et Marie Curie University, INSERM U943, Paris, France
    Antivir Ther 17:119-23. 2012
    ..The aim of this study was to characterize the mutations selected upon failure on etravirine (ETR)-containing regimen in non-nucleoside reverse transcriptase inhibitors (NNRTIs)-experienced HIV-infected patients and the associated factors...
  16. ncbi request reprint Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice
    Sidonie Lambert-Niclot
    AP HP, Pitie Salpetriere Hospital, INSERM U943 and Pierre et Marie Curie University, Paris, France
    J Antimicrob Chemother 67:2487-93. 2012
    ..Virological failures of lopinavir/ritonavir and their effects on the resistance to protease inhibitors and reverse transcriptase inhibitors were evaluated in protease inhibitor-experienced patients...
  17. doi request reprint Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients
    Sarah Maylin
    Laboratoire de Virologie, Hopital Saint Louis, AP HP, Paris, France
    AIDS 26:939-49. 2012
    ..Although their quantification is useful for other antivirals, such has not been the case with tenofovir disoproxil fumarate (TDF), particularly in HIV infection...
  18. doi request reprint Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial
    Véronique Avettand-Fenoel
    AP HP, Laboratoire de Virologie, CHU Necker Enfants Malades, Paris, France
    J Antimicrob Chemother 65:1005-7. 2010
    ..To study the impact of protease inhibitor monotherapy on the HIV-1 blood reservoir in 72 antiretroviral-naive patients...
  19. ncbi request reprint Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients
    Constance Delaugerre
    Department of Virology, Ambroise Pare Hospital, APHP, Boulogne, France
    AIDS 21:1210-3. 2007
    ..These key amprenavir mutations were also selected at the time of failure, suggesting their impact on darunavir efficacy...
  20. pmc Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Antimicrob Agents Chemother 54:72-7. 2010
    ..In conclusion, ETR was associated with high response rates in NNRTI-experienced patients in combination with other active drugs regardless of the therapeutic class used...
  21. doi request reprint A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure
    Anne Genevieve Marcelin
    Laboratoire de Virologie, AP HP, Groupe Hospitalier Pitie Salpetriere, UPMC Univ Paris 06, INSERM U943, Paris, France
    Int J Antimicrob Agents 42:42-7. 2013
    ..RAL showed great potency in treatment-experienced patients. The number of new drugs associated with RAL was an important factor associated with VR. HIV-1 subtype and baseline integrase polymorphisms do not influence the RAL VR...
  22. doi request reprint Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus
    Sarah Maylin
    Laboratoire de Virologie, Hopital Saint Louis, Paris, France
    J Clin Virol 56:306-11. 2013
    ..No direct comparison has been made between assays that quantify HBeAg...
  23. doi request reprint Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy
    Sidonie Lambert-Niclot
    AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University, Paris, France
    J Antimicrob Chemother 67:1470-4. 2012
    ....
  24. pmc Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    Antimicrob Agents Chemother 48:4687-92. 2004
    ....
  25. ncbi request reprint Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial)
    Constance Delaugerre
    Department of Virology EA2387, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 8:233-7. 2003
    ..To assess the effect of interleukin (IL)-2 combined with highly active antiretroviral therapy (HAART) on HIV-1 pro-viral DNA quantification in HIV-1-infected patients with CD4<200/mm3...
  26. doi request reprint Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial
    Sebastien Gallien
    Department of Infectious Diseases, Assistance Publique Hopitaux de Paris, Saint Louis Hospital, Paris, France
    J Antimicrob Chemother 66:2099-106. 2011
    ..To assess the sustainable efficacy and safety of a switch from enfuvirtide to raltegravir in patients with multidrug-resistant HIV infection...
  27. pmc Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome
    Constance Delaugerre
    EA 3620 MRT, Descartes University, Paris, France
    Retrovirology 6:85. 2009
    ..Primary-HIV-1-infection in newborns that occurs under antiretroviral prophylaxis that is a high risk of drug-resistance acquisition. We examine the frequency and the mechanisms of resistance acquisition at the time of infection in newborns...
  28. ncbi request reprint Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study
    Dominique Costagliola
    INSERM, Unité Mixte de Recherche UMR S 720, Universite Pierre et Marie Curie Paris 6, Paris, France
    J Acquir Immune Defic Syndr 46:12-8. 2007
    ..Surveillance of HIV-1 drug resistance in antiretroviral-treated patients is important from the public health perspective of the spread of resistance and to evaluate the proportion of patients for whom new drugs are needed...
  29. ncbi request reprint Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance
    Diane Descamps
    Laboratoire de Virologie, CHU Bichat Claude Bernard, Paris, France
    J Med Virol 78:153-60. 2006
    ..077). No errors were made by 19% of laboratories in 2002, compared to 42% in 2003. These results show the value of repeated external quality assessments...
  30. pmc Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine
    Constance Delaugerre
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    Antimicrob Agents Chemother 46:1586-8. 2002
    ....
  31. ncbi request reprint Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial
    Vincent Calvez
    Department of Virology and Infectious Diseases and Pitie Salpetrière Hospital, Paris, France
    Antivir Ther 7:211-8. 2002
    ....
  32. ncbi request reprint Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission
    Constance Delaugerre
    Department of Virology EA2387 and Infectious Diseases, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 9:415-21. 2004
    ..To understand the virological mechanisms of 2-year persistence of multidrug-resistant virus without selective antiretroviral pressure in HIV-1-infected patients...
  33. pmc Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients
    Constance Delaugerre
    Laboratoire de Virologie, Hôpital Saint Louis APHP, Paris, France
    PLoS ONE 7:e36673. 2012
    ..Our objective was to determine the emergence and evolution of DRAM during LLV in HIV-1-infected patients while receiving antiretroviral therapy (ART)...
  34. pmc Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen
    Jade Ghosn
    Paris Descartes University, EA 3620, Necker University Hospital, Paris, France
    PLoS ONE 6:e24798. 2011
    ..We show that pre-therapy mutations in gag cleavage site sequence were significantly associated with the virological outcome of a first-line LPV/r single drug regimen in the Monark trial...
  35. pmc Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy
    Constance Delaugerre
    University Paris Descartes, EA 3620, Virology Department, Necker Hospital AP HP, Paris, France
    Antimicrob Agents Chemother 53:2934-9. 2009
    ..The mutation L76V may be considered in further studies of lopinavir resistance...
  36. doi request reprint Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen
    Constance Delaugerre
    Virology Department, INSERM U941 Paris 7 Diderot University, Saint Louis Hospital APHP, Paris, France
    AIDS 24:2391-5. 2010
    ..In vitro, integrase inhibitors reduce proviral DNA levels and rapidly increase 2-long-terminal repeat (LTR) circle levels. We examined the effect of raltegravir on the time course of HIV-1 DNA forms in patients with controlled viremia...
  37. pmc Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus
    Sarah Maylin
    Laboratoire de Virologie, Hopital Saint Louis, AP HP, Paris, France
    Clin Vaccine Immunol 19:242-8. 2012
    ..078). In conclusion, the Elecsys assay, with automatic on-board dilution, is capable of quantifying serum HBsAg levels in HIV-HBV-coinfected patients, with very high correlation with the Architect assay...
  38. pmc Clinical and resistance consequences of misquantification of plasma and cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype G-infected patient
    Constance Delaugerre
    Department of Virology, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75010 Paris, France
    J Clin Microbiol 47:3763-4. 2009
    ..We report a case of underquantification of HIV type 1 (HIV-1) RNA in plasma and cerebrospinal fluid from an HIV-1 subtype G-infected woman, leading to delayed diagnosis of HIV encephalitis and to the emergence of drug resistance...
  39. doi request reprint Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France
    Diane Descamps
    Laboratoire de Virologie, AP HP Groupe hospitalier Bichat Claude Bernard and EA 4409 Université Paris Diderot Paris 7, Paris, France
    J Antimicrob Chemother 65:2620-7. 2010
    ..To estimate the prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-1-infected patients in France...
  40. pmc Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients
    Anne Genevieve Marcelin
    Department of Virology, INSERM EMI 0214, Bichat Claude Bernard Hospital, Paris, France
    Antimicrob Agents Chemother 47:594-600. 2003
    ....
  41. doi request reprint Lack of benefit of 3-month intensification with enfuvirtide plus optimized background regimen (OBR) versus OBR alone in patients with multiple therapeutic failures: the INNOVE study
    Laurence Morand-Joubert
    Laboratory of Virology, AP HP, CHU Saint Antoine, UPMC University Paris 06, INSERM U943, Paris, France
    J Med Virol 84:1710-8. 2012
    ..A 3-month short-course intensified treatment with ENF did not improve Week-24 virological response in treatment-experienced patients infected with HIV-1 harboring resistant viruses that were still susceptible to two antiretroviral drugs...
  42. ncbi request reprint HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors
    Jade Ghosn
    Universite Paris Descartes, EA MRT 3620, Laboratoire de Virologie, AP HP, CHU Necker Enfants Malades, Paris, France
    AIDS Rev 11:165-73. 2009
    ..The first data on rilpivirine resistance are encouraging, but still too preliminary...
  43. doi request reprint National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011
    Diane Descamps
    Laboratoire de Virologie, AP HP Groupe hospitalier Bichat Claude Bernard and EA 4409 Université Paris Diderot, Paris 7, PRES Sorbonne Paris Cité, Paris, France
    J Antimicrob Chemother 68:2626-31. 2013
    ..As recommended by the French ANRS programme for the surveillance of HIV-1 resistance, we estimated the prevalence of transmitted drug resistance-associated mutations (RAMs) in antiretroviral-naive, chronically HIV-1-infected patients...
  44. doi request reprint Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial
    Nathalie de Castro
    Department of Infectious Diseases, Assistance Publique Hopitaux de Paris, Saint Louis Hospital and University of Paris VII Denis Diderot, Paris, France
    Clin Infect Dis 49:1259-67. 2009
    ..We conducted a prospective, randomized, open-label trial to compare the antiviral efficacy and safety of a switch to raltegravir with the efficacy and safety of continuing enfuvirtide...
  45. pmc Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients
    Anders Boyd
    1 INSERM, UMRS707, Paris, France
    AIDS Res Hum Retroviruses 29:1535-40. 2013
    ..8). Interferon therapy might be more effective after extended previous anti-HBV antiviral exposure among triinfected patients; however, the long-term implications of these findings remain unknown...
  46. doi request reprint Sexually transmitted hepatitis C virus superinfection in HIV/hepatitis C virus co-infected men who have sex with men
    Jade Ghosn
    AP HP, EA MRT 3620, Universite Paris Descartes, Department of Virology, Necker Hospital, Paris, France
    AIDS 22:658-61. 2008
    ..HCV serology and serum HCV RNA should be examined periodically in HIV-infected men who have sex with men engaging in high-risk sexual behaviours...
  47. doi request reprint Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B
    Hai Le Nguyen
    Virology Department, INSERM U941 Paris 7 Diderot University, Saint Louis Hospital APHP, Paris, France
    Intervirology 55:287-95. 2012
    ..The genetic barrier for the evolution of integrase inhibitors (INIs) including raltegravir (RAL), elvitegravir (EVG), and dolutegravir (DTG) resistance was compared between HIV-1 subtypes CRF01_AE and B...
  48. doi request reprint Prevalence of antibodies and RNA genome of hepatitis E virus in a cohort of French immunocompromised
    Sarah Maylin
    Virology Dpt, INSERM U941 Paris 7 Diderot University, Saint Louis Hospital APHP, Paris, France
    J Clin Virol 53:346-9. 2012
    ..Recently, cases of chronic hepatitis E have been identified in immunocompromised patients...
  49. doi request reprint Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assays
    Jean Marie Sire
    Laboratoire de Virologie, Hôpital Saint Louis AP HP, INSERM U941, Universite Paris Diderot, Paris, France
    J Acquir Immune Defic Syndr 56:239-43. 2011
    ..A new version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 assay (CA/CTM v2.0) has been introduced to overcome the underquantification observed with the first version...
  50. doi request reprint Higher Specificity of Nucleic Acid Sequence-Based Amplification Isothermal Technology than of Real-Time PCR for Quantification of HIV-1 RNA on Dried Blood Spots
    Séverine Mercier-Delarue
    Laboratoire de Virologie, AP HP Hôpital Saint Louis, INSERM U941 Université Paris Diderot, Sorbonne Paris Cité, Paris, France
    J Clin Microbiol 52:52-6. 2014
    ..This higher specificity of NASBA technology could avoid overestimation of poor compliance or the emergence of resistance when monitoring antiretroviral efficacy with the DBS method. ..
  51. pmc Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe?
    Jean Michel Molina
    INSERM U941, University of Paris Diderot, Sorbonne Paris Cité, Paris, France
    BMC Med 11:186. 2013
    ..Alternatives to a daily oral PrEP regimen are being explored. ..
  52. ncbi request reprint [Is HIV more and more resistant?]
    Marie Laure Chaix
    Laboratoire de Virologie, Hopital Necker Enfants Malades, 75743 Paris 15
    Rev Prat 54:471-4. 2004
  53. ncbi request reprint Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)
    Christine Katlama
    Département des Maladies Infectieuses et Tropicales INSERM E 0214, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    AIDS 18:217-26. 2004
    ..Both highly potent antiretroviral drug rescue therapy and treatment interruption have been suggested to be effective in patients with multiple treatment failure...
  54. pmc Pressure from TRIM5α contributes to control of HIV-1 replication by individuals expressing protective HLA-B alleles
    Clémence Granier
    INSERM U941, Paris, France
    J Virol 87:10368-80. 2013
    ....
  55. doi request reprint Characterization of CRF56_cpx, a new circulating B/CRF02/G recombinant form identified in MSM in France
    Marie Leoz
    aLaboratoire associé au CNR du VIH, Hopital Ch Nicolle, CHU de Rouen bGRAM EA 2656, Faculte de Medecine Pharmacie, Universite de Rouen, Rouen, France cComputational and Evolutionary Biology research group, Faculty of Life Science, University of Manchester, Manchester, UK dAssistance Publique Hopitaux de Paris, Groupe Hospitalier Bichat Claude Bernard, Service de Virologie eAssistance Publique Hopitaux de Paris, Groupe Hospitalier Saint Louis, Service de Virologie, fAssistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie Salpetriere, Service de Virologie, Paris, France
    AIDS 27:2309-12. 2013
    ..We describe this new Circulating Recombinant Form, CRF56_cpx, estimate the time to its most recent common ancestor, investigate its origins and show that it probably shares common ancestors with strains from the East Mediterranean. ..
  56. doi request reprint Antiretroviral therapy initiation in france: adherence to national guidelines and outcome
    Vatthanaphone Latthaphasavang
    1Department of Infectious Diseases, Saint Louis Hospital, AH HP, and University of Paris Diderot, Paris, France
    J Int Assoc Physicians AIDS Care (Chic) 11:40-6. 2012
    ..Retrospective study of all patients who started antiretroviral therapy (ART) in 2007 in a single center in Paris, with baseline characteristics and 1-year outcome, to assess adherence to national guidelines...
  57. pmc Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting
    Juliette Pavie
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, Universite Paris Diderot, Paris, France
    PLoS ONE 5:e11581. 2010
    ..Several HIV rapid tests are now licensed in Europe but their sensitivity on total blood and/or oral fluid in routine healthcare settings is not known...
  58. doi request reprint Clinical Evaluation of BioPlex 2200 HIV Ag-Ab, an Automated Screening Method Providing Discrete Detection of HIV-1 p24 Antigen, HIV-1 Antibody, and HIV-2 Antibody
    Maud Salmona
    Microbiology Laboratory, APHP Hôpital Saint Louis, Paris, France
    J Clin Microbiol 52:103-7. 2014
    ....
  59. doi request reprint Failure of fourth-generation enzyme immunoassay in hiv screening and plasma HIV-1 RNA detection in recent high-risk behavior
    Sarah Maylin
    Laboratoire de Microbiologie, AP HP Hôpital Saint Louis, Paris, France
    Intervirology 57:49-51. 2014
    ..Detection of plasma HIV-1 RNA concomitant with screening tests may be proposed in individuals presenting with a symptomatic sexually transmitted infection...
  60. doi request reprint AIDS-related Kaposi's sarcoma can occur during peginterferon-α and ribavirin therapy for chronic hepatitis C infection
    Victoire de Lastours
    1Infectious Diseases Department, Assistance Publique Hopitaux de Paris APHP, Hopital Saint Louis, Paris, France
    J Int Assoc Physicians AIDS Care (Chic) 11:9-11. 2012
    ..Before the arrival of highly active antiretroviral therapy (HAART), interferon α has been used successfully to treat AIDS-related Kaposi's sarcoma (KS). Peginterferon-α (pegIFN-α) may still be used successfully in refractory KS...
  61. doi request reprint Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients
    Jean Francois Delfraissy
    AP HP, Department of Internal Medicine and Infectious Diseases, Bicetre University Hospital, Le Kremlin Bicetre, France
    AIDS 22:385-93. 2008
    ..Guidelines for the use of antiretroviral agents for HIV-1 infection recommend combining at least three agents. The toxicity, cost, and complexity of such regimens warrant the search for other options...
  62. doi request reprint HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide
    Diane Descamps
    AP HP, Groupe Hospitalier Bichat Claude Bernard, Laboratoire de Virologie, Paris F 75018, France
    J Antimicrob Chemother 62:451-5. 2008
    ..We studied gp41 mutations associated with failing enfuvirtide salvage therapy...
  63. ncbi request reprint Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results from a randomized control trial
    Vincent Thibault
    Hepatology 35:238-9. 2002
  64. pmc Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years
    Vincent Jullien
    Service de Pharmacologie Clinique, Groupe Hospitalier Cochin Saint Vincent De Paul, 74 82 Avenue Denfert Rochereau, 75674 Paris Cedex 14, France
    Antimicrob Agents Chemother 50:3548-55. 2006
    ..The consequences of these pharmacokinetic discrepancies and the necessity to modify the currently recommended dosage regimen should be further investigated...